Physiologic granulocyte destruction in vivo by apoptosis.
A Michael
AM
Peters
Jessica F
JF
White
Edwin R
ER
Chilvers
D000818:Animals; D017304:Annexin A5 / Q000493:pharmacokinetics*; D017209:Apoptosis / Q000187:drug effects*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006098:Granulocytes / Q000000981:diagnostic imaging / Q000187:drug effects; D020287:In Situ Nick-End Labeling; D008114:Liver Neoplasms, Experimental / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D008297:Male; D009368:Neoplasm Transplantation; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D051381:Rats; D017208:Rats, Wistar; D012016:Reference Values; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014018:Tissue Distribution; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured
D017304:Annexin A5; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C417036:technetium Tc 99m annexin V; D003520:Cyclophosphamide